ROBERT WALLEN: Open Payments
NPI 1609583517 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,415 in 131 payments from 17 companies in 2025. Trend: 2023 $29 · 2024 $833 · 2025 $2,415
Food & beverage: $2,415
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $476 |
| ABBVIE INC. | 34 | $435 |
| Indivior Inc. | 9 | $250 |
| Vanda Pharmaceuticals Inc. | 13 | $234 |
| Alkermes, Inc. | 6 | $132 |
| Braeburn Inc. | 5 | $128 |
| E.R. Squibb & Sons, L.L.C. | 3 | $119 |
| Teva Pharmaceuticals USA, Inc. | 5 | $103 |
| Neurocrine BioSciences, Inc. | 3 | $97 |
| Corium, LLC | 7 | $82 |
Products named: CAPLYTA, VRAYLAR, SUBLOCADE, FANAPT, BRIXADI, COBENFY, INGREZZA, Azstarys.
Industry payments across AZ — which companies pay providers there.
